Cambridge Investment Research Advisors
GTHX

Cambridge Investment Research Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,711
Closed -$38K – 3543
2024
Q2 		$38K Sell
16,711
-100
-0.6% -$382 ﹤0.01% 3239
2024
Q1 		$73K Buy
16,811
+5,000
+42% +$17.4K ﹤0.01% 3183
2023
Q4 		$36K Buy
+11,811
New +$22.2K ﹤0.01% 3117
2022
Q1 		– Sell
-12,667
Closed -$129K – 3341
2021
Q4 		$129K Sell
12,667
-4,250
-25% -$54.2K ﹤0.01% 2997
2021
Q3 		$227K Buy
16,917
+3,812
+29% +$62.1K ﹤0.01% 2706
2021
Q2 		$288K Buy
13,105
+4,753
+57% +$106K ﹤0.01% 2501
2021
Q1 		$201K Buy
+8,352
New +$194K ﹤0.01% 2624

Cambridge Investment Research Advisors's GTHX Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 16,711 shares — an estimated $38K sold.

Cambridge Investment Research Advisors first reported a position in GTHX in Q1 2021 and held it in 7 quarters. The position peaked at $288K in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Cambridge Investment Research Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 16,711 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $38K.
  • Cambridge Investment Research Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Cambridge Investment Research Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $288K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.